CLINICAL TRIALS PROFILE FOR BREXPIPRAZOLE
✉ Email this page to a colleague
All Clinical Trials for Brexpiprazole
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01360632 ↗ | Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | 2011-06-01 | To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT |
| NCT01360645 ↗ | Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial) | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | 2011-07-01 | To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT |
| NCT01360866 ↗ | Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | 2011-10-01 | To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD) |
| NCT01668797 ↗ | Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia | Completed | Quintiles, Inc. | Phase 3 | 2012-10-01 | The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia. |
| NCT01668797 ↗ | Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | 2012-10-01 | The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia. |
| NCT01670279 ↗ | Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder | Completed | H. Lundbeck A/S | Phase 1 | 2012-07-01 | The purpose of this study is to assess the safety and tolerability of ascending multiple oral doses of brexpiprazole as adjunctive therapy in the treatment of elderly subjects with MDD. |
| NCT01670279 ↗ | Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | 2012-07-01 | The purpose of this study is to assess the safety and tolerability of ascending multiple oral doses of brexpiprazole as adjunctive therapy in the treatment of elderly subjects with MDD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Brexpiprazole
Condition Name
Clinical Trial Locations for Brexpiprazole
Trials by Country
Clinical Trial Progress for Brexpiprazole
Clinical Trial Phase
Clinical Trial Sponsors for Brexpiprazole
Sponsor Name
